An unnecessary FDA policy is making it nearly impossible for schizophrenics without stable medical care to get clozapine, the ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...
Weeks after that announcement, BMS announced a $14 billion deal to buy Karuna Therapeutics, whose M1- and M4-targeting schizophrenia drug was already under FDA review. The September approval of ...
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...
Zacks.com on MSN7h
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline SetbackThe third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...
AbbVie (ABBV) shares dropped 11% premarket as late-stage trials for schizophrenia drug emraclidine did not meet primary ...
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
The FDA's REMS program has been found to have unintentionally created barriers to accessing clozapine, a crucial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback